As previously noted by Wang et al. [19], mTOR can regulate E2F1 expression, and inhibition of mTOR with the pharmacological agent, rapamycin led to reduced protein levels of E2F1 in non-small cell lung cancer cells [19]. Here, E2F1 is linked to non-small cell lung carcinoma.